目的: 检测原发性IgA肾病患者及健康人群血清标本中MBL、MASP-2的浓度,研究其在IgA肾病中的作用。方法: 选取2020年12月~2021年12月在包头医学院第一附属医院肾内科首次经肾穿刺活检确诊为IgA肾病的患者33例作为IgAN组,同期在同一医院体检的健康志愿者33例作为健康对照组。用ELISA法测定两组血清MBL、MASP-2浓度,分析血清MBL、MASP-2浓度与临床指标、病理参数的关系。结果: IgAN组患者血清MBL浓度高于健康对照组,MASP-2浓度两组间无差异。IgAN患者血清MBL与24hUP、LDL-C、UA、T≥1呈正相关,与ALB呈负相关,血清MASP-2与ESR呈正相关。结论: 补体MBL途径参与IgAN的疾病过程,IgAN患者血清MBL浓度增高与尿蛋白量增多、血白蛋白降低、嘌呤及脂代谢异常、肾小管/间质损伤有关,高浓度的血清MBL可能是IgAN发生发展的重要因素。IgAN患者血清MASP-2浓度的增高可能伴随疾病慢性炎症状态。
Objective: To detect the concentration of MBL and MASP-2 in serum samples of patients with primary IgA nephropathy and healthy people, and to study its role in IgA nephropathy. Methods: Thirty-three patients with IgA nephropathy diagnosed by renal biopsy for the first time in the Department of Nephrology of the First Affiliated Hospital of Baotou Medical College from December 2020 to December 2021 were selected as the IgAN group, and 33 healthy volunteers who underwent physical examination in the same hospital during the same period were selected as the healthy control group. Serum MBL and MASP-2 concentrations were measured by ELISA, and the relationship between serum MBL and MASP-2 concentrations and clinical indicators and pathological parameters was analyzed. Results: The serum MBL concentration in IgAN group was higher than that in healthy control group, and there was no difference in MASP-2 concentration between the two groups. The serum MBL of IgAN patients was positively correlated with 24 hUP, LDL-C, UA and T≥1, and negatively correlated with ALB. The serum MASP-2 was positively correlated with ESR. Conclusion: Complementary MBL pathway is involved in the disease process of IgAN. The increase of serum MBL concentration in IgAN patients is related to the increase of urinary protein, the decrease of serum albumin, the abnormality of purine and lipid metabolism, and the injury of renal tubule / interstitial. High concentration of serum MBL may be an important factor in the occurrence and development of IgAN. Increased serum MASP-2 levels in IgAN patients may be associated with chronic inflammation.
[1] Zhu L, Zhang H. The genetics of IgA nephropathy: an overview from China[J]. Kidney Dis (Basel), 2015,1(1):27-32.
[2] Lai KN, Tang SC, Schena FP, et al. IgA nephropathy[J].Nat Rev Dis Primers, 2016, 2:16001.
[3] Jarrick S, Lundberg S, Welander A, et al. Mortality in IgA nephropathy: a nationwide population-based cohort study[J].J Am SocNephrol, 2019, 30(5):866-876.
[4] Medjeral-Thomas NR, O'Shaughnessy MM. Complement in IgA nephropathy: the role of complement in the pathogenesis, diagnosis, and future management of IgA nephropathy[J].Adv Chronic Kidney Dis, 2020, 27(2): 111- 119.
[5] Gaya da Costa M, Poppelaars F, van Kooten C, et al. Age and sex-associated changes of complement activity and complement levels in a healthy caucasian population[J].Front Immunol, 2018, 9: 2664.
[6] Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group[J].Kidney Int, 2017, 91(5): 1014- 1021.
[7] 中国医师协会肾脏内科医师分会, 中国中西医结合学会肾脏疾病专业委员会. 中国肾性高血压管理指南2016(简版)[J]. 中华医学杂志, 2017, 97(20)1547-1555.
[8] 朱林波. MBL与FGFR4的相互作用及其对人肾系膜细胞作用的研究[D]. 沈阳:中国医科大学, 2018.
[9] Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease[J].J Am SocNephrol, 2006, 17(6): 1724- 1734.
[10] Ohsawa I, Ishii M, Ohi H, et al. Pathological scenario with the mannose-binding lectin in patients with IgA nephropathy[J].J Biomed Biotechnol, 2012, 2012:476739.
[11] Guo WY, Zhu L, Meng SJ, et al. Mannose-binding lectin levels could predict prognosis in IgA nephropathy[J].J Am SocNephrol, 2017,28(11):3175-3181.
[12] Konieczny A, Donizy P, Gołębiowski T, et al. Clinical and histopathological factors influencing IgA nephropathy outcome[J].Diagnostics (Basel), 2021, 11(10): 1764.
[13] Lu P, Li X, Zhu N, et al. Serum uric acid level is correlated with the clinical, pathological progression and prognosis of IgA nephropathy: an observational retrospective pilot-study[J].PeerJ, 2020, 8:e10130.
[14] Lee C, Park JT, Chang TI, et al. Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD[J].Nutr Metab Cardiovasc Dis, 2022, 32(2): 410- 419.
[15] Zhao YF, Zhu L, Liu LJ, et al. Measures of urinary protein and albumin in the prediction of progression of IgA nephropathy[J].Clin J Am Soc Nephrol, 2016, 11(6):947-955.
[16] 郑林花, 张颖, 宋莎莎, 等. 血清MASP2、MASP3在IgA肾病中的作用[J]. 中国免疫学杂志, 2020, 36(1)77-83.
